Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
- Published: December 2010
- Your are here:
- Home
- Categories
- Pharmaceuticals and Healthcare
- Pharmaceuticals
Exploring New Opportunities in the Expanding Diabetes Market: Novel Targets and Strategies
Exploring New Opportunities in the Expanding Diabetes Market: Novel Targets and Strategies
- Published: February 2011
- Region: World
- 42 Pages
- Decision Resources, Inc
FEATURED COMPANIES
- Alantos Pharmaceuticals
- Boehringer Ingelheim
- Exelixis
- Kissei Pharmaceutical
- Novo Nordisk
- Servier
- MORE
The expanding diabetes market is opening up new and lucrative opportunities for companies with innovative technologies and experimental candidates. The launch of novel agents and a steady increase in the drug-treated patient population are fueling growth in this market. The R&D pipeline includes drugs against the promising novel targets SGLT, PTP1B, 11ß-HSD1, and others; clinical trials testing disease-modifying agents for type 1 diabetes are also under way.
Questions answered in this report:
- Type 2 diabetes is a significant public health threat and an important and growing pharmaceutical market; type 1 diabetes also continues to suffer from significant unmet needs. How large is the current market for type 1 and type 2 diabetes? How much will this market grow over the next ten years? What factors will drive this market growth?
- Unmet needs in type 2 diabetes have led to a flurry of R&D activity and a dense development pipeline. What novel diabetes targets hold the most promise for drug discovery and development? Which new treatment strategies are being pursued, and which are the most advanced?
- The need for disease-modifying therapies,
READ MORE >
Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction to the Diabetes Market
Type 1 Diabetes
- Disease Overview
- Current Therapies
Type 2 Diabetes
- Disease Overview
- Insulin Resistance
- Defects in Insulin Secretion
- Excess Hepatic Glucose Production
- Current Therapies
Key Novel Drug Targets for Type 2 Diabetes
- Sodium-Dependent Glucose Cotransporter Inhibitors
- Protein Tyrosine Phosphatase 1B Inhibitors
- 11ß-Hydroxysteroid Dehydrogenase Inhibitors
- Centrally Acting Drugs
- Inhibitors of Inflammation
- Glucokinase Activators
- Diacylglycerol Acetyl Transferase Inhibitors
- G-Protein-Coupled Receptor 119 Agonists
- G-Protein-Coupled Receptor 40 Agonists
- Sirtuin Activators
Novel Approaches to Insulin Delivery
- Inhaled Insulin
- Buccal Delivery
Spectrum Expert Commentary: The Opportunity for Inhaled Insulin
Emerging Immunomodulatory Mechanisms for Type 1 Diabetes
- Anti-CD Monoclonal Antibodies
- DiaPep277
- Diamyd
- BHT-3021
- Exsulin
- Prochymal
Strategic Partnering in Diabetes: Innovation in R&D
Outlook for Novel Approaches to Treating Type 1 and Type 2 Diabetes
Bibliography
About the Author
- Alantos Pharmaceuticals
- Alizé Pharma
- Amgen
- Amylin Pharmaceuticals
- Anchor Therapeutics
- Andromeda Biotech
- Animas
- Arena Pharmaceuticals
- Array Biopharma
- Ascendis Pharma
- Astellas
- AstraZeneca
- Bayhill Therapeutics
- Biocompatibles
- Biocon
- Biovitrum
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Catabasis
- Cellartis/Lund University
- Cengent Therapeutics
- ChemoCentryx
- Chiesi Farmaceutici
- Clal Biotechnology Industries
- CureDM
- Dainippon Sumitomo
- DepoMed
- DeveloGen
- Diamyd Medical
- Daiichi Sankyo
- Eli Lilly
- Envoy Therapeutics
- Evotec
- Exelixis
- Exsulin
- Forest Laboratories
- Galapagos
- Genaera
- Genentech
- Generex Biotechnology
- Genzyme
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Human Genome Sciences
- Incyte
- Inhale Therapeutic Systems (now Nektar Therapeutics)
- iNovacia
- Ipsen
- Isis Pharmaceuticals
- Janssen-Cilag
- Johnson & Johnson/Mitsubishi Tanabe
- Juvenile Diabetes Research Foundation
- Kissei Pharmaceutical
- Kotobuki
- Lexicon Pharmaceuticals
- Ligand Pharmaceuticals
- Macrogenics
- MannKind
- Marcadia Biotech
- MedImmune
- Medingo
- Merck
- Merck KGaA
- Merrion Pharmaceuticals
- Metabasis Therapeutics
- Metabolex
- Nektar Therapeutics (formerly Inhale Therapeutic Systems)
- Neurocrine Biosciences
- Novartis
- Novo Nordisk
- OctoPlus
- Ono Pharmaceutical
- Ortho-McNeil-Janssen
- Ortho-McNeil Pharmaceutical
- OSI Pharmaceuticals
- Osiris
- Palatin Technologies
- PDL Biopharma
- Pfizer
- Phenomix
- Plexxikon
- Prosidion
- Rhythm Pharmaceuticals
- Roche
- Sanofi-Aventis
- SciGen
- Servier
- Sirtris Pharmaceuticals
- SmartCells
- Swedish Orphan Biovitrum
- Taisho Pharmaceuticals
- Takeda
- Teva
- Theratechnologies
- Tolerx
- Transition Therapeutics
- TransTech Pharma
- VeroScience
- Vitae Pharmaceuticals
- Vivus
- Wellstat Therapeutics
- Xoma
- Yissum Research Development of Hebrew University
| Format | Properties | |
|---|---|---|
| Electronic (PDF) | The report will be emailed to you. The report is sent in PDF format. | This is a single user license, allowing one specific user access to the product. |
| Enterprisewide | The report will be emailed to you. The report is sent in PDF format. | This is an enterprise license, allowing all employees within your organisation access to the product. |
Note: Product cover images may vary from those shown
RELATED PRODUCTS
-
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
FROM -
R&D Trends: Insulin Antidiabetics - The Future is Analogs
- Published: May 2011
FROM -
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
- Language: English
- 416 Pages
- Published: December 2010
- Region: World
FROM -
Pipeline Insight: Insulin Antidiabetics - Novel analogs show promise as alternative delivery methods prove less attractive.
Pipeline Insight: Insulin Antidiabetics - Novel analogs show promise as alternative delivery methods prove less attractive.
- Language: English
- 177 Pages
- Published: December 2010
- Region: World
FROM -
European Diabetes Therapeutics Market
- Language: English
- 151 Pages
- Published: September 2011
- Region: Europe
FROM -
Neuroprotection - Drugs, Markets and Companies
- Language: English
- 669 Pages
- Published: June 2013
- Region: World
FROM -
Nitric Oxide - Therapeutics, Markets and Companies
- Language: English
- 274 Pages
- Published: June 2013
- Region: World
FROM -
The Global Diabetes Market: Therapeutics, Diagnostics and Complications
- Language: English
- 218 Pages
- Published: August 2006
- Region: World
FROM -
Biotech Investment and Business Trends: Surviving the Long Road to Market
- Language: English
- Published: May 2011
- Region: World
FROM -
Type 2 Diabetes (Event Driven)
- Language: English
- 263 Pages
- Published: November 2012
- Region: World
